CSL Ltd
AUAUDCSL Ltd (US:CMXHF) — Biotechnology. Numero di borse in cui sono quotate le azioni della società: 2. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- csl.com.au
- Relazioni con gli Investitori
- investors.csl.com/
- Settore
- Healthcare · Biotechnology
- Sede Centrale
- Melbourne, Australia
- Amministratore Delegato
- Gordon Naylor BEng
- Dipendenti
- 29 000
- Fondata
- 1994
- Azioni in Circolazione
- 479.88 Mln
- Flottante
- 478.53 Mln
- Capitalizzazione di Mercato
- 87.08 Mld AUD
- Insider
- 0.02%
- Investitori Istituzionali
- 38.27%
- Forma Giuridica
- R4KK
- ISIN
- AU000000CSL8
- LEI
- 529900ECSECK5ZDQTE14
- Payout Ratio
- perdita
- FCF
- 2.23 Mld USD
- Pagamenti / FCF
- 70%
- Debito
- 10.9 Mld USD3.5 anni di FCF
- Serie di Dividendi
- 31 a.
- Utili, FCF e dividendi pagati — per i 12 mesi fino a 30.06.2026 (l'ultimo rapporto dell'azienda).
- NAV
Descrizione
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Dividendi
CSL Ltd (CSL) paga dividendi due volte l'anno. All'anno (12 mesi fino all'ultimo pagamento annunciato): 4.0536 AUD per azione (pagamenti: 2). Questo rappresenta circa il 2.10% del prezzo attuale delle azioni. In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 10.03.2027. Storia dei dividendi ininterrotta: 31 anni.
| Data Ex | Pagamento | Importo | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-09-09 | — | 2.2438 AUD | 1.3/2.3 % | semestrale | AU:CSL |
| 2026-03-10 | — | 1.8098 AUD | 1.3/3.0 % | semestrale | AU:CSL |
| 2025-09-09 | — | 2.4508 AUD | 1.1/2.1 % | semestrale | AU:CSL |
| 2025-03-10 | — | 2.0727 AUD | 0.8/1.6 % | semestrale | AU:CSL |
| 2024-09-09 | — | 2.1746 AUD | 0.7/1.3 % | semestrale | AU:CSL |
| 2024-03-11 | — | 1.7989 AUD | 0.6/1.3 % | semestrale | AU:CSL |
| 2023-09-11 | — | 2.0078 AUD | 0.7/1.3 % | semestrale | AU:CSL |
| 2023-03-09 | — | 1.6215 AUD | 0.5/1.1 % | semestrale | AU:CSL |
| 2022-09-06 | — | 1.7583 AUD | 0.6/1.1 % | semestrale | AU:CSL |
| 2022-03-07 | — | 1.4229 AUD | 0.6/0.6 % | semestrale | AU:CSL |
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.49% | 7.16 Mln | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.99% | 4.75 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 0.75% | 3.6 Mln | 2026-08-31 |
| Fidelity Concord Street… | 0.39% | 1.89 Mln | 2026-07-31 |
| iShares Trust-iShares MS… | 0.36% | 1.72 Mln | 2026-08-31 |
| J.P. Morgan Exch-Trd Fd.… | 0.3% | 1.45 Mln | 2026-07-31 |
| Fidelity Salem Street TR… | 0.29% | 1.38 Mln | 2026-07-31 |
| iShares Trust-iShares MS… | 0.28% | 1.35 Mln | 2026-08-31 |
| VANGUARD Intl Eqy. INDEX… | 0.24% | 1.16 Mln | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.22% | 1.08 Mln | 2026-05-31 |
| Pacer Advisors, Inc. | 0.08% | 369 774 | 2026-06-30 |
| Naylor (Gordon) (Directo… | ≈0.01% | 40 819 | 2026-05-26 |
| McKenzie (Paul F) (Chief… | ≈0.01% | 31 053 | 2025-09-01 |
| McNamee (Brian Anthony)… | ≈0.01% | 30 561 | 2026-08-21 |
| Linton (Joy) (Chief Fina… | ≈0% | 15 096 | 2025-06-30 |
| Watkins (Alison Mary) (I… | ≈0% | 6 989 | 2026-08-21 |
| Clark (Megan Elizabeth)… | ≈0% | 5 718 | 2025-08-22 |
| Schmeltz (Andy) (Other E… | ≈0% | 5 067 | 2025-06-30 |
| Hewson (Carolyn Judith)… | ≈0% | 4 131 | 2026-08-21 |
| Price (Cameron Bruce) (I… | ≈0% | 3 559 | 2026-08-21 |
| Daniels (Brian M.D.) (No… | ≈0% | 3 400 | 2025-11-18 |
